Streetbeat News

Regulatory

BIOR

Biora Therapeutics has been granted an extension by Nasdaq to regain compliance with its listing requirements. This extension provides the company with additional time to meet the necessary criteria to remain listed on the exchange.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 12:01 pm

BTCUSD

Arthur Hayes, co-founder of BitMEX, suggests that the Federal Reserve's monetary policy may be influenced by the upcoming U.S. presidential election, potentially leading to interest rate cuts to stimulate the stock market. This could result in increased liquidity and a bullish market sentiment.

Portfolio Pulse from Murtuza Merchant

August 28, 2024 | 11:39 am

COSM

VRAX

Virax Biolabs Group Limited (NASDAQ:VRAX) has signed a distribution agreement for Mpox virus detection kits in Europe and the Middle East. The kits are approved for sale in Europe and authorized by the UK's regulatory agency. Cosmos Health Inc. (NASDAQ:COSM) retains distribution rights in Greece, Cyprus, and non-exclusive rights across Europe. VRAX stock was down 4.70% in premarket trading.

Portfolio Pulse from Vandana Singh

August 28, 2024 | 11:16 am

VRAX

Virax Biolabs has announced that its RT PCR Mpox virus detection kits are CE-marked for sale in Europe and authorized by the UK's MHRA, indicating regulatory approval for these markets.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 11:15 am

META

Nearly half of OpenAI's AGI safety researchers have resigned, citing a shift in focus from safety to commercial product development. This includes notable figures like Jan Hendrik Kirchner and cofounder John Schulman. The resignations highlight a broader debate on AI safety and regulation, with OpenAI facing criticism for opposing California's AI regulation bill. In response, OpenAI has appointed Irina Kofman, a former Meta executive, to focus on safety and preparedness.

Portfolio Pulse from Benzinga Neuro

August 28, 2024 | 10:47 am

SWTX

SpringWorks' Mirdametinib has received validation from the European Medicines Agency for treating NF1-PN in adults and children. The FDA has granted multiple designations, including Orphan Drug and Fast Track, indicating strong regulatory support.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 10:35 am

SWTX

SpringWorks Therapeutics announced that the FDA has accepted its New Drug Application for Mirdametinib, a treatment for Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, and granted it Priority Review with a PDUFA date set for February 28, 2025.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 10:33 am

NVS

Novartis' Phase 3 V MONO study for Leqvio (Inclisiran) met its primary endpoints, showing effectiveness in lowering LDL cholesterol compared to placebo and ezetimibe in patients at low or moderate risk of atherosclerotic cardiovascular disease.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 10:13 am

AVGO

MSFT

NVDA

OpenAI's collaboration with Arizona State University (ASU) has resulted in 250 AI projects, integrating AI into education and research. This partnership is part of a broader trend of AI integration, with OpenAI also partnering with Condé Nast and Apple. Microsoft faces EU scrutiny over its investment in OpenAI, and OpenAI is in talks with Broadcom to develop a new AI chip.

Portfolio Pulse from Benzinga Neuro

August 28, 2024 | 9:38 am

AMZN

GOOG

GOOGL

Anthropic, backed by Google and Amazon, has updated system prompts for its AI platform Claude.ai and mobile apps. These updates do not affect the API. The Claude 3.5 Sonnet model is highlighted for its advanced capabilities. Anthropic faces a UK investigation and a class-action lawsuit.

Portfolio Pulse from Benzinga Neuro

August 28, 2024 | 9:11 am